Acticor: tender extended, no response to date

(CercleFinance.com) - Acticor Biotech, a biopharmaceutical company in receivership, announced on Thursday that the courts had granted it time to find new investors or a buyer.


With no response to date, the court-appointed administrator has granted the company an extension of the current call for tenders until Tuesday November 5.

In a press release, Acticor explains that this extension should enable it to continue its search for new investors or partners to support its new development plan in ST-segment elevation myocardial infarction (STEMI).

This repositioning follows the failure, last July, of its Phase 2/3 trial in the treatment of mechanical thrombectomy in acute ischemic stroke.

In a press release issued on Monday, Acticor - which only has a cash flow horizon until January 2025 - had made its repositioning project conditional on obtaining financing.

The company's shares, listed on the Paris Bourse, fell by over 15% on Thursday morning in the wake of these announcements.

Copyright (c) 2024 CercleFinance.com. All rights reserved.